Edinburgh Research Explorer

Cardiomyocyte and vascular smooth muscle independent 11β-hydroxysteroid dehydrogenase 1 amplifies infarct expansion, hypertrophy and the development of heart failure following myocardial infarction in male mice

Research output: Contribution to journalArticlepeer-review

Related Edinburgh Organisations

Open Access permissions



  • Download as Adobe PDF

    Rights statement: This article has been published under the terms of the Creative Commons Attribution License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s)

    Final published version, 2.37 MB, PDF document

    Licence: Creative Commons: Attribution (CC-BY)

Original languageEnglish
Pages (from-to)346–357
Issue number1
Early online date14 Oct 2015
Publication statusPublished - 1 Jan 2016


Global deficiency of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), an enzyme that regenerates glucocorticoids within cells, promotes angiogenesis and reduces acute infarct expansion following myocardial infarction (MI) suggesting that 11β-HSD1 activity has an adverse influence on wound healing in the heart after MI. The present study investigated whether 11β-HSD1 deficiency could prevent the development of heart failure following MI, and examined whether 11β-HSD1 deficiency in cardiomyocytes and vascular smooth muscle cells confers this protection. Male mice with global deficiency in 11β-HSD1, or with Hsd11b1 disruption in cardiac and vascular smooth muscle (via SM22α-Cre recombinase) underwent coronary artery ligation for induction of MI. Acute injury was equivalent in all groups. However, by 8 weeks after induction of MI, relative to C57Bl/6 wild type, globally 11β-HSD1 deficient mice had reduced infarct size (34.7±2.1%LV vs 44.0±3.3%LV, P=0.02), improved function (ejection fraction 33.5±2.5% vs 24.7±2.5%, P=0.03) and reduced ventricular dilation (LVEDV 0.17±0.01ml vs 0.21±0.01ml, P=0.01). This was accompanied by a reduction in hypertrophy, pulmonary edema and in the expression of genes encoding atrial natriuretic peptide and β-myosin heavy chain. None of these outcomes, nor promotion of peri-infarct angiogenesis during infarct repair, were recapitulated when 11β-HSD1 deficiency was restricted to cardiac and vascular smooth muscle. 11β-HSD1 expressed in cells other than cardiomyocytes or vascular smooth muscle limits angiogenesis and promotes infarct expansion with adverse ventricular remodeling after MI. Early pharmacological inhibition of 11β-HSD1 may offer a new therapeutic approach to prevent heart failure associated with ischemic heart disease.

Download statistics

No data available

ID: 22064963